{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:21:07Z","timestamp":1761740467672},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T00:00:00Z","timestamp":1144368000000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> Infectious complication represents a significant source of morbidity and mortality in heart transplant recipients. To assess humoral immunity markers that can predict the development of infection, 38 consecutive recipients of heart transplants performed at a single center were prospectively studied. Induction therapy included daclizumab. Immunoglobulin (IgG, IgA, IgM) and complement factors (C3, C4, and factor B) were performed by nephelometry in peripheral blood samples obtained before transplantation, and 7 days and 1 month after transplantation. During a mean follow\u2010up of 16.9 months, 13 patients had at least one episode of infection (34.2%). Eight of these were cytomegalovirus (CMV) infections treated with intravenous ganciclovir, 2 were bacterial pneumonia, 1 patient had bacterial septicemia, 1 patient had urinary tract infection, and 1 patient had pulmonary nocardiosis. No significant association was found between infection and age, sex, immunosuppression, CMV serostatus of donor and recipient, or treated rejection episodes. Pre\u2010transplant IgG (below median value=1140\u2003mg\/dL; relative risk [RR] 3.69; 95% confidence interval [CI] 1.01\u201313.54; <jats:italic>P<\/jats:italic>=0.04) and post\u2010transplant IgG levels at day 7 (below median value=679\u2003mg\/dL; RR 11.21; CI 1.04\u201389.48; <jats:italic>P<\/jats:italic>=0.022) were associated with an increase in the risk for developing infections. Early monitoring of immunoglobulin levels might help to identify the risk for developing infection in heart transplantation.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2006.00136.x","type":"journal-article","created":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T08:28:54Z","timestamp":1144398534000},"page":"49-53","source":"Crossref","is-referenced-by-count":40,"title":["IgG monitoring to identify the risk for development of infection in heart transplant recipients"],"prefix":"10.1111","volume":"8","author":[{"given":"E.","family":"Sarmiento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Rodriguez\u2010Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fernandez\u2010Ya\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Palomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Urrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bouza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fernandez\u2010Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/322733"},{"key":"e_1_2_6_3_2","first-page":"796","article-title":"The registry of the international society for heart and lung transplantation","volume":"23","author":"Taylor DO","year":"2004","journal-title":"twenty-first official adult heart transplant report-2004"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-199603000-00013"},{"key":"e_1_2_6_5_2","first-page":"329","article-title":"Risk factors for early, cumulative, and fatal infections after heart transplantation","volume":"15","author":"Smart FW","year":"1996","journal-title":"a multiinstitutional study"},{"key":"e_1_2_6_6_2","first-page":"394","article-title":"Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group","volume":"13","author":"Kirklin JK","year":"1994","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_6_7_2","first-page":"636","article-title":"Risk factors of invasive aspergillosis after heart transplantation","volume":"4","author":"Mu\u00f1oz P","year":"2004","journal-title":"protective role of oral itraconazole prophylaxis"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.2.398"},{"key":"e_1_2_6_9_2","first-page":"133","article-title":"Significant post\u2010transplant hypogammaglobulinemia in six heart transplant recipients","volume":"2","author":"Corales R","year":"2000","journal-title":"an emerging clinical phenomenon?"},{"key":"e_1_2_6_10_2","first-page":"425","article-title":"Hypogammaglobulinemia following cardiac transplantation","volume":"20","author":"Yamani MH","year":"2001","journal-title":"a link between rejection and infection"},{"issue":"2","key":"e_1_2_6_11_2","first-page":"40","article-title":"Hypogammaglobulinemia after heart transplantation","volume":"3","author":"Yamani MH","year":"2001","journal-title":"impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes"},{"key":"e_1_2_6_12_2","first-page":"97","article-title":"Hypogammaglobulinemia after heart transplantation","volume":"5","author":"Sarmiento E","year":"2005","journal-title":"use of intravenous immunoglobulin replacement therapy in relapsing CMV disease"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.2.569"},{"key":"e_1_2_6_14_2","first-page":"339","article-title":"Neutralization of cytomegalovirus virions","volume":"176","author":"Spiller OB","year":"1997","journal-title":"the role of complement"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00915482"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2006.00136.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2006.00136.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:06:47Z","timestamp":1696946807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2006.00136.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1399-3062.2006.00136.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2006.00136.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}